Article    Table of Contents                    Full Text of this article    PDF of this article (PDFs free after 6 months)    Summary for Patients    Figures/Tables List    Related articles in Annals  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Rudolph, R. E.    Reid, B. J.    Related Articles in PubMed    PubMed Citation    PubMed

ARTICLE

Effect of Segment Length on Risk for Neoplastic Progression in Patients with Barrett Esophagus

Rebecca E. Rudolph, MD, MPH; Thomas L. Vaughan, MD, MPH; Barry E. Storer, PhD; Rodger C. Haggitt, MD; Peter S. Rabinovitch, MD, PhD; Douglas S. Levine, MD; and Brian J. Reid, MD, PhD

18 April 2000 | Volume 132 Issue 8 | Pages 612-620

Background: The increased risk for esophageal adenocarcinoma associated with long-segment ( 3 cm) Barrett esophagus is well recognized. Recent studies suggest that short-segment (<3 cm) Barrett esophagus is substantially more common; however, the risk for neoplastic progression in patients with this disorder is largely unknown.

Objective: To examine the relation between segment length and risk for aneuploidy and esophageal adenocarcinoma in patients with Barrett esophagus.

Design: Prospective cohort study.

Setting: University medical center in Seattle, Washington.

Patients: 309 patients with Barrett esophagus.

Measurements: Patients were monitored for progression to aneuploidy and adenocarcinoma by repeated endoscopy with biopsy for an average of 3.8 years. Cox proportional-hazards analysis was used to calculate adjusted relative risks and 95% CIs.

Results: After adjustment for histologic diagnosis at study entry, segment length was not related to risk for cancer in the full cohort (P > 0.2 for trend). When patients with high-grade dysplasia at baseline were excluded, however, a nonsignificant trend was observed; based on a linear model, a 5-cm difference in segment length was associated with a 1.7-fold (95% CI, 0.8-fold to 3.8-fold) increase in cancer risk. Among all eligible patients, a 5-cm difference in segment length was associated with a small increase in the risk for aneuploidy (relative risk, 1.4 [CI, 1.0 to 2.1]; P = 0.06 for trend). A similar trend was observed among patients without high-grade dysplasia at baseline.

Conclusions: The risk for esophageal adenocarcinoma in patients with short-segment Barrett esophagus was not substantially lower than that in patients with longer segments. Although our results suggest a small increase in risk for neoplastic progression with increasing segment length, additional follow-up is needed to determine whether the patterns of risk occurred by chance or represent true differences. Until more data are available, the frequency of endoscopic surveillance should be selected without regard to segment length.

Author and Article Information

From Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington

Acknowledgments: The authors thank Dr. Patricia Blount for her contributions to patient care in the Seattle Barrett's Esophagus Project, Ms. Carissa Sanchez for flow cytometric analyses, Mr. David Cowan and Ms. Janine Kikuchi for database management, Ms. Christine Karlsen and Ms. Sue Irvine for their contributions as patient care coordinators, and Ms. Tricia Christopherson for management of patient interviews.

Grant Support: By National Institutes of Health grants R01 CA61202 and R25 CA57734.

Requests for Single Reprints: Rebecca E. Rudolph, MD, MPH, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, MP-474, Box 19024, Seattle, WA 98109-1024.

Requests To Purchase Bulk Reprints (minimum, 100 copies): the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints{at}mail.acponline.org.

Current Author Addresses: Drs. Rudolph, Vaughan, Storer, and Reid: Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, MP-474, Box 19024, Seattle, WA 98109-1024.

Dr. Haggitt: University of Washington Medical Center, Pathology, BB-210B, Box 356100, Seattle, WA 98195.

Dr. Rabinovitch: University of Washington, K-081 Health Sciences Pathology, Box 357470, Seattle, WA 98195.

Dr. Levine: AstraZeneca Pharmaceuticals, 725 Chesterbrook Boulevard, E-2C, Wayne, PA 19087-5677.

Author Contributions: Conception and design: R.E. Rudolph, T.L. Vaughan, D.S. Levine, B.J. Reid.

Analysis and interpretation of the data: R.E. Rudolph, T.L. Vaughan, B.E. Storer, R.C. Haggitt, P.S. Rabinovitch, D.S. Levine, B.J. Reid.

Drafting of the article: R.E. Rudolph, T.L. Vaughan.

Critical revision of the article for important intellectual content: R.E. Rudolph, T.L. Vaughan, B.E. Storer, R.C. Haggitt, P.S. Rabinovitch, D.S. Levine, B.J. Reid.

Final approval of the article: R.E. Rudolph, T.L. Vaughan, B.E. Storer, R.C. Haggitt, P.S. Rabinovitch, D.S. Levine, B.J. Reid.

Provision of study materials or patients: T.L. Vaughan, R.C. Haggitt, D.S. Levine, B.J. Reid.

Statistical expertise: R.E. Rudolph, T.L. Vaughan, B.E. Storer.

Obtaining of funding: T.L. Vaughan, P.S. Rabinovitch, B.J. Reid.

Administrative, technical, or logistic support: T.L. Vaughan, P.S. Rabinovitch, B.J. Reid.

Collection and assembly of data: R.E. Rudolph, T.L. Vaughan, R.C. Haggitt, P.S. Rabinovitch, D.S. Levine, B.J. Reid.

Related articles in Annals:

Summaries for Patients
Risk for Cancer in Patients with Barrett Esophagus

Annals 2000 132: 612. [Full Text]  

Letters
Segment Length and Risk for Neoplastic Progression in Patients with Barrett Esophagus
Hashem B. El-Serag

Annals 2000 133: 747-748. [Full Text]  

Letters
Segment Length and Risk for Neoplastic Progression in Patients with Barrett Esophagus
Rebecca E. Rudolph, Thomas L. Vaughan, AND Barry Storer

Annals 2000 133: 748. [Full Text]  

This article has been cited by other articles:

				F. Yousef, C. Cardwell, M. M. Cantwell, K. Galway, B. T. Johnston, and L. Murray The Incidence of Esophageal Cancer and High-Grade Dysplasia in Barrett's Esophagus: A Systematic Review and Meta-Analysis Am. J. Epidemiol., August 1, 2008; 168(3): 237 - 249. [Abstract] [Full Text] [PDF]

				Z. Jin, J. P. Hamilton, J. Yang, Y. Mori, A. Olaru, F. Sato, T. Ito, T. Kan, Y. Cheng, B. Paun, et al. Hypermethylation of the AKAP12 Promoter is a Biomarker of Barrett's-Associated Esophageal Neoplastic Progression Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 111 - 117. [Abstract] [Full Text] [PDF]

				Z. Jin, A. Olaru, J. Yang, F. Sato, Y. Cheng, T. Kan, Y. Mori, C. Mantzur, B. Paun, J. P. Hamilton, et al. Hypermethylation of Tachykinin-1 Is a Potential Biomarker in Human Esophageal Cancer Clin. Cancer Res., November 1, 2007; 13(21): 6293 - 6300. [Abstract] [Full Text] [PDF]

				S. R. DeMeester Adenocarcinoma of the Esophagus and Cardia: A Review of the Disease and Its Treatment Ann. Surg. Oncol., January 1, 2006; 13(1): 12 - 30. [Abstract] [Full Text] [PDF]

				M. B. Cook, C. P. Wild, and D. Forman A Systematic Review and Meta-Analysis of the Sex Ratio for Barrett's Esophagus, Erosive Reflux Disease, and Nonerosive Reflux Disease Am. J. Epidemiol., December 1, 2005; 162(11): 1050 - 1061. [Abstract] [Full Text] [PDF]

				R. E. Rudolph, T. L. Vaughan, A. R. Kristal, P. L. Blount, D. S. Levine, P. C. Galipeau, L. J. Prevo, C. A. Sanchez, P. S. Rabinovitch, and B. J. Reid Serum Selenium Levels in Relation to Markers of Neoplastic Progression Among Persons With Barrett's Esophagus J Natl Cancer Inst, May 21, 2003; 95(10): 750 - 757. [Abstract] [Full Text] [PDF]

				S. J. Spechler A 59-Year-Old Woman With Gastroesophageal Reflux Disease and Barrett Esophagus JAMA, January 22, 2003; 289(4): 466 - 475. [Full Text] [PDF]

				N L A Arents, J C Thijs, and J H Kleibeuker A rational approach to uninvestigated dyspepsia in primary care: review of the literature Postgrad. Med. J., December 1, 2002; 78(926): 707 - 716. [Abstract] [Full Text] [PDF]

				R J Playford Endoscopic surveillance of patients with Barrett's oesophagus Gut, September 1, 2002; 51(3): 314 - 315. [Full Text]

				R C Fitzgerald, S Abdalla, B A Onwuegbusi, P Sirieix, I T Saeed, W R Burnham, and M J G Farthing Inflammatory gradient in Barrett's oesophagus: implications for disease complications Gut, September 1, 2002; 51(3): 316 - 322. [Abstract] [Full Text]

				T. L. Vaughan, A. R. Kristal, P. L. Blount, D. S. Levine, P. C. Galipeau, L. J. Prevo, C. A. Sanchez, P. S. Rabinovitch, and B. J. Reid Nonsteroidal Anti-inflammatory Drug Use, Body Mass Index, and Anthropometry in Relation to Genetic and Flow Cytometric Abnormalities in Barrett's Esophagus Cancer Epidemiol. Biomarkers Prev., August 1, 2002; 11(8): 745 - 752. [Abstract] [Full Text] [PDF]

				N. Shaheen and D. F. Ransohoff Gastroesophageal Reflux, Barrett Esophagus, and Esophageal Cancer: Scientific Review JAMA, April 17, 2002; 287(15): 1972 - 1981. [Abstract] [Full Text] [PDF]

				S. J. Spechler Barrett's Esophagus N. Engl. J. Med., March 14, 2002; 346(11): 836 - 842. [Full Text] [PDF]

				D. J. Wong, T. G. Paulson, L. J. Prevo, P. C. Galipeau, G. Longton, P. L. Blount, and B. J. Reid p16INK4a Lesions Are Common, Early Abnormalities that Undergo Clonal Expansion in Barrett's Metaplastic Epithelium Cancer Res., November 1, 2001; 61(22): 8284 - 8289. [Abstract] [Full Text] [PDF]

				G. M. R. Campos, S. R. DeMeester, J. H. Peters, S. Oberg, P. F. Crookes, J. A. Hagen, C. G. Bremner, L. F. Sillin III, R. J. Mason, and T. R. DeMeester Predictive Factors of Barrett Esophagus: Multivariate Analysis of 502 Patients With Gastroesophageal Reflux Disease Arch Surg, November 1, 2001; 136(11): 1267 - 1273. [Abstract] [Full Text] [PDF]

				Segment Length and Risk of Neoplastic Progression in Barrett's Esophagus Journal Watch Gastroenterology, August 14, 2000; 2000(814): 2 - 2. [Full Text]